Vincerx Pharma, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering and advancing innovative treatments for cancer, specifically addressing areas of high medical need within the U.S. Its primary therapeutic asset is VIP152, an inhibitor targeting cyclin-dependent kinase-9 (CDK9), designed for individuals battling advanced forms of cancer. Beyond this lead candidate, the company's pipeline features several preclinical-stage projects: VIP217, an orally administered PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate aimed at solid tumor treatment; and VIP943 and VIP924, both geared towards treating blood cancers. Established in 2019, Vincerx Pharma is based in Palo Alto, California.
The current price of VINC is $0.01 USD — it has decreased by -15.33% in the past 24 hours. Watch Vincerx Pharma stock price performance more closely on the chart.
What is Vincerx Pharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Vincerx Pharma stocks are traded under the ticker VINC.
Is Vincerx Pharma stock price growing?▼
VINC stock has fallen by -2.31% compared to the previous week, the month change is a -2.31% fall, over the last year Vincerx Pharma has showed a -71.78% decrease.
What is Vincerx Pharma market cap?▼
Today Vincerx Pharma has the market capitalization of 66,471.8
What is Vincerx Pharma revenue for the last year?▼
Vincerx Pharma revenue for the last year amounts to 0 USD.
What is Vincerx Pharma net income for the last year?▼
VINC net income for the last year is -30.07M USD.
How many employees does Vincerx Pharma have?▼
As of July 18, 2026, the company has 12 employees.
In which sector is Vincerx Pharma located?▼
Vincerx Pharma operates in the Health & Wellness sector.
When did Vincerx Pharma complete a stock split?▼
The last stock split for Vincerx Pharma was on January 28, 2025 with a ratio of 1:20.
Where is Vincerx Pharma headquartered?▼
Vincerx Pharma is headquartered in San Mateo, United States.